This analytical retrospective observational study demonstrated no differences in the proportion of patients with HER2-positive breast cancer who achieved a pCR with neoadjuvant treatment with and without anthracyclines (AC-THP 58.3% and TCbHP 60.4%, p = 0.84). The gene discussed is ERBB2; the disease is breast carcinoma.